Michael Rich

6 ta ish

Partners In Health

1. Principles for designing future regimens for multidrug-resistant tuberculosis

   Grania Brigden, Bern-Thomas Nyang’wa, Philipp du Cros +9

   MaqolaOAOchiq kirish20133 iqtibos

   ABIABI:AkademIndex/2026.other.006845

2. Counting Pyrazinamide in Regimens for Multidrug-Resistant Tuberculosis

   Molly F. Franke, Mercedes C. Becerra, Dylan B. Tierney +5

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.027991

3. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

   Dennis Falzon, E. Jaramillo, Holger J. Schünemann +43

   MaqolaOAOchiq kirish20113 iqtibos

   ABIABI:AkademIndex/2026.other.169932

4. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations

   Francis Varaine, Lorenzo Guglielmetti, Helena Huerga +5

   Boshqa20162 iqtibos

   ABIABI:AkademIndex/2026.other.027998

5. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

   Oleksandr Korotych, Jay Achar, Elmira Gurbanova +23

   MaqolaOAOchiq kirish20240 iqtibos

   ABIABI:AkademIndex/2024.article.018556

6. Effectiveness and Safety of Modified Fully Oral Nine-Month Treatment Regimens for Rifampicin-Resistant Tuberculosis: Prospective Cohort Study

   Oleksandr Korotych, Jay Achar, Elmira Gurbanova +23

   PreprintOAOchiq kirishTuberculosis Research and EpidemiologySSRN Electronic Journal20240 iqtibos

   ABIABI:AkademIndex/2024.preprint.000046